Biotechs fight fears of ‘antibiotic apocalypse’
02 September 2019
Market failure gives little incentive to develop new drugs as antimicrobial resistance grows.
Carb-X and Repair Impact Fund to fund R&D of novel antibiotics. However, Pharma needs to take over later in the development.
Further reading: Financial Times
Author(s): Clive Cookson
Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
LifeArc |
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Ambassador Network
Join the AMR Insights Ambassador Network today!
Connect to over 550 AMR professionals and students in 60 countries!
